Fifth International Workshop on the Biology, Preventions and Treatment of Relapse after Hematopoietic Stem Cell Transplantation and Cellular Therapy
October 7-9, 2021

DESCRIPTION

The course will provide a forum for participants to learn about and discuss the latest techniques and therapeutic options for treating Relapse after Hematopoietic Stem Cell Transplantation including the relative biology, greatest deficits in current research, and topics of future study relative to the biology, natural history, prevention and treatment of relapse following allogeneic hematopoietic stem cell transplantation.

TARGET AUDIENCE

This activity is designed for medical and pediatric hematologists and oncologists, hematopoietic stem and immune cell translational and basic scientists, hematopathologists, physicians-in-training, advance practice providers, pharmacists, oncology nurses and other healthcare professionals dedicated to providing the highest level of care in hematopoietic stem cell transplantation.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- State the basic mechanisms of relapse after transplant and cellular therapies;
- Recognize risk factors for relapse after transplant and cellular therapies;
- Identify strategies to prevent relapse after transplant and cellular therapies;
- Identify treatment strategies that can be used to treat patients who have relapsed after transplant;
- Recognize the importance of clinical trials in this patient population.

ACCREDITATION AND CREDIT DESIGNATION

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 15.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.

EDUCATIONAL GRANTS/COMMERCIAL SUPPORT

Educational grant funding has been generously provided by:

Astellas Pharma Global Development, Inc.
Bristol-Myers Squibb
Genzyme Corporation
Novartis Pharmaceuticals Corporation
Omeros
Pfizer Inc.

We also thank our exhibitors:

Gold Level
Bristol Myers Squibb

Silver Level
Astellas Oncology
Incyte
Jazz Pharmaceuticals
Kite
Medexus Pharma
Sanofi

Classic Level
Legend Biotech
Taiho Oncology, Inc.
Pfizer Oncology
Actinium Pharmaceuticals, Inc.
Novartis

Additional Level
Gamida Cell
Amgen
Omeros
ADC Therapeutics
CareDX
CSL Behring
Merck
InstilBio
Nektar
Pharmacyclics
Sobi
NMDP/Be The Match
Iovance

DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

COURSE FACULTY

The following individuals have no relevant financial relationships with ineligible companies to disclose:

Michael Abele, MD
Ana Alarcon Tomas, MD
Veronika Bachanova, MD, PhD
Samuel F. Bakhoum, MD, PhD
Ezhilarasi Chendamarai, PhD
Peter Dreger, MD
Nico Gagelmann, MD
Valentina Gambacorta, PhD
Mary Horowitz, MD, MS
Xiao-Jun Huang, MD
Katharine Hsu, MD, PhD
Eric Leifer, PhD
Claudia Lengerke, MD, PhD
Shannon McCurdy, MD
Simone Minnie, PhD
Effie Petersdorf, MD
David Ritchie, MD, PhD
Nirali Shah, MD
Jay Spiegel, MD
Erietta Stelekati, PhD
Takanori Teshima, MD
John Vaughn, MD, MS

Michael R. Bishop, MD has served as a consultant for Novartis, Kite/Gilead, BMS, CRISPR Therapeutics, and Autolus Ltd. Dr. Bishop has served on the steering committee for Novartis and CRISPR Therapeutics and on the speakers bureau for Kite/Gilead, BMS, and Incyte.

JJ Boelens, MD, PhD has served as a consultant for Avrobio, Omeros, Bluerock, Race Oncology, Sanofi, and Medexus. Dr. Boelens has received grant funding from Sanofi.

Catherine Bollard, MD has served on the advisory board of Cellectis and BMS and on the data science monitoring board of SOBI. Dr. Bollard is a cofounder of Mana Therapeutics and Catamaran Bio, a board member of Cabaletta Bio, and owns stock in Repertoire Immune Medicines and Neximmune.

Jaebok Choi, PhD has received grant funding from Mallinckrodt Pharmaceuticals and Aravive, Inc.

Charles Craddock, MD, PhD has received research funding from Kite and Jazz and served on the speakers bureau for Astellas, AbbVie, Janssen, Novartis, Roche, BMS, Pfizer, Daiichi Sankyo, and Eurocept. Dr. Craddock has served as a consultant and advisor for AbbVie, Janssen, Novartis, BMS, Pfizer, Astellas, Daiichi Sankyo, and Eurocept and as a consultant for Kite, Jazz, and Roche.

Marcos de Lima, MD has served on the scientific advisory board of BMS, Pharmacyclics, Celgene, and Pfizer and has received research funding from Lentigen/Miltenyi Biotec, Celgene, and Pfizer.

John F. DiPersio, MD, PhD has served as a consultant and advisory committee member for Rivervest and Incyte. Dr. DiPersio has ownership interest in Magenta and WUGEN and has received research support from NeoImmuneTech, Macrogenics, and Bioline.

Hermann Einsele, MD has served as a consultant for BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, and Novartis. Dr. Einsele has received research funding from BMS/Celgene, Janssen, Amgen, Sanofi, and GSK.

Joseph Fraietta, PhD has served as a consultant for Shennon Biotherapeutics and Cacography Biotherapeutics, as a scientific advisory board member for DeCART Therapeutics and Cacography Biotherapeutics, and as a co-founder of DeCART Therapeutics. Dr. Fraietta has received research funding from Tmunity Therapeutics.

Sergio Giralt, MD has served as a consultant for Celgene, Bristol Myers Squbb, Amgen, Kite, Novartis, and Jazz.

Philip Greenberg, MD has received research support from Juno Therapeutics. Dr. Greenberg will discuss the investigational use of experimental engineered T cell therapy in my presentation

Boglarka Gyurkocza, MD has received research funding from Actinium. Dr. Gyurkocza will discuss fludarabine, tacrolimus, etc. in the setting of hematopoietic cell transplantation.

Mehdi Hamadani, MD has served as a consultant for Janssen, Incyte Corporation, ADC Therapeutics, Omeros, and Kite and on the speaker’s bureau for Sanofi, AstraZeneca, and BeiGene. Dr. Hamadani has received research funding from Takeda, Spectrum, and Sanofi.

Christopher Hourigan, DM, DPhil, FACP, FRCP has received research funding from Sellas.

Meagan Jacoby, MD, PhD has no relevant financial relationships with ineligible companies to disclose. Dr. Jacoby will discuss the investigator-initiated, institutional-trial "Pre-emptive Therapy with DEC-C to Improve Outcomes in MDS Patients with Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant."

Krishna Komanduri, MD has served as a consultant for Kite/Gilead, Novartis, Iovance, Kiadis, Takeda, and Genentech/Roche.

Nicolaus Kröger, MD has received research funding from Neovii, Novartis, Celgene, and Riemser and has served as a speaker and on the advisory board for Neovii, Novartis, Celgene, and Jazz.

Philip McCarthy, MD has served as a consultant for BlueBird Biotech, Bristol-Myers Squibb, Celgene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Oncopeptides, Sanofi, Takeda and has received grant funding from Celgene. Dr. McCarthy will discuss non-EMA and non-FDA approved indications.

Mark Levis, MD, PhD has served as a consultant for Astellas, Daiichi-Sankyo, Menarini, Abbvie, and Amgen and has received research funding from Astellas and FujiFilm.

Jonathan Peled, MD, PhD has served as a consultant for Davoltera, CSL Behring, and MaaT Pharma. Dr. Peled has IP licensing with and has received research funding from Seres Therapeutics.

Karl Peggs, MB, Bch, MRCP, FRCPath has served as Chief Medical Officer for Achilles Therapeutics Ltd, and as an advisor for Autolus Therapeutics.

David Porter, MD has served on the advisory board for Novartis, Kite/Gilead, Incyte, Janssen, and Jazz. Dr. Porter receives royalties from intellectual property from Tmunity and Novartis and has received research funding from Novartis.

Susan Prockop, MD has received research funding from Atara Biotherapeutics and Mesoblast and is the inventor of IP licensed to Atara. Dr. Prockop will discuss the off-label use of rituximab.

Michael Pulsipher, MD has served on the advisory board of Novartis and Medexus and has served on the CTL019 steering committee of Novartis. Dr. Pulsipher has been an educator for Bellicum, Miltenyi, and Adaptive.

Rizwan Romee, MD has served on the scientific advisory board of and as a consultant for Glycostem and has received research support from CRISPR Therapeutics, Miltenyi Biotech, Akron Biotech, and Skyline Therapeutics.

Rayne Rouce, MD has served on the advisory board of Novartis, as a consultant for Pfizer, and has received research funding from Tessa Therapeutics. Dr. Rouce will discuss the unapproved/investigational use of NK and iNKT cells, including CAR-modified ones for treatment of relapsed or refractory cancers.

Michael Sadelain, MD, PhD has received research funding from Takeda.

Brenda Sandmaier, MD has served as a consultant for Actinium Pharmaceuticals, Jazz Pharmaceuticals, and AbbVie. Dr. Sandmaier has intellectual property licensed to AbbVie. Dr. Sandmaier will discuss drugs used for conditioning and GVHD for hematopoietic cell transplantation regimens.

Christoph Schmid, MD, PhD has served on the speakers' bureau for Novartis, Roche, BMS, and Eurocept and on the advisory board member for Novartis, Daichii, Roche, Eurocept. Dr. Schmid has received research funding from Novartis, Roche, Abbvie, and Neovii.

Thomas Schroder, MD has received research funding from Celgene.

Bart Scott, MD has served as a consultant for Consulting for Alexion, BMS, and Jazz and received research funding from Novartis and BMS.

Melody Smith, MD, MS has served as a consultant for Janssen.

Robert Soiffer, MD has served as a consultant for Takeda, on the Data Safety Monitoring Board for Juno Therapeutics/Celgene/BMS, and as chair of the grant review committee for Gilead.

Luca Vago, MD, PhD has received research funding from Moderna Therapeutics.

Alan Wayne, MD has received research funding from Spectrum/Acrotech, Servier, and Kite Pharma.

The staff of the Center for Continuing Medical Education have no relevant financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

DISCLAIMER

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Please Note: Requests to claim *AMA PRA Category 1 Credit*™ after three months will be subject to additional fees.